Literature DB >> 19200948

Abnormal motor cortex excitability in preclinical and very early Huntington's disease.

Sven Schippling1, Susanne A Schneider, Khailash P Bhatia, Alexander Münchau, John C Rothwell, Sarah J Tabrizi, Michael Orth.   

Abstract

BACKGROUND: In Huntington's disease (HD), the cerebral cortex is involved early in the disease process. The study of cortical excitability can therefore contribute to understanding HD pathophysiology.
METHODS: With transcranial magnetic stimulation (TMS) we examined motor cortex excitability in 8 premanifest HD gene carriers, 8 very early symptomatic HD patients, and 22 healthy control subjects. Electrophysiological measures were correlated with the clinical stage of HD to identify motor cortical dysfunction before overt clinical disease onset.
RESULTS: Premanifest and early manifest HD patients had higher resting and active motor cortex thresholds than control subjects (p = .024). At rest, recruitment of motor evoked potentials was more gradual in both patient groups than in control subjects (p = .001). When active, recruitment and the duration of the cortical silent period were similar in all groups. There was a tendency for short interval intra-cortical inhibition to have a higher threshold in all patients taken together but not in each group separately. Short latency afferent inhibition (SAI) was reduced in early manifest patients compared with control subjects and premanifest patients (p < .001) and in contrast to all other measures was inversely associated with estimated time to onset (p = .013, adjusted R(2) = .32) and the Unified Huntington's Disease Rating Scale motor score (p = .001, adjusted R(2) = .5). A combination of age, CAG repeat length, and SAI strongly predicted the Unified Huntington's Disease Rating Scale motor score (p = .001, adjusted R(2) = .68).
CONCLUSIONS: Our findings add to the evidence for early cortical involvement in HD possibly before HD signs appear.

Entities:  

Mesh:

Year:  2009        PMID: 19200948      PMCID: PMC2998173          DOI: 10.1016/j.biopsych.2008.12.026

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  39 in total

1.  Quantitative neuropathological changes in presymptomatic Huntington's disease.

Authors:  E Gómez-Tortosa; M E MacDonald; J C Friend; S A Taylor; L J Weiler; L A Cupples; J Srinidhi; J F Gusella; E D Bird; J P Vonsattel; R H Myers
Journal:  Ann Neurol       Date:  2001-01       Impact factor: 10.422

2.  Short-interval paired-pulse inhibition and facilitation of human motor cortex: the dimension of stimulus intensity.

Authors:  Tihomir V Ilić; Frank Meintzschel; Ulrich Cleff; Diane Ruge; Kirn R Kessler; Ulf Ziemann
Journal:  J Physiol       Date:  2002-11-15       Impact factor: 5.182

3.  Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation.

Authors:  Vincenzo Di Lazzaro; A Oliviero; P A Tonali; C Marra; A Daniele; P Profice; E Saturno; F Pilato; C Masullo; J C Rothwell
Journal:  Neurology       Date:  2002-08-13       Impact factor: 9.910

4.  Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex.

Authors:  V Di Lazzaro; A Oliviero; P Profice; M A Pennisi; S Di Giovanni; G Zito; P Tonali; J C Rothwell
Journal:  Exp Brain Res       Date:  2000-12       Impact factor: 1.972

5.  The prolonged cortical silent period in patients with Huntington's disease.

Authors:  N Modugno; A Currà; M Giovannelli; A Priori; F Squitieri; S Ruggieri; M Manfredi; A Berardelli
Journal:  Clin Neurophysiol       Date:  2001-08       Impact factor: 3.708

6.  Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.

Authors:  M Suzuki; T J Desmond; R L Albin; K A Frey
Journal:  Synapse       Date:  2001-09-15       Impact factor: 2.562

7.  Short latency inhibition of human hand motor cortex by somatosensory input from the hand.

Authors:  H Tokimura; V Di Lazzaro; Y Tokimura; A Oliviero; P Profice; A Insola; P Mazzone; P Tonali; J C Rothwell
Journal:  J Physiol       Date:  2000-03-01       Impact factor: 5.182

8.  Mice transgenic for exon 1 of Huntington's disease: properties of cholinergic and dopaminergic pre-synaptic function in the striatum.

Authors:  J M Vetter; T Jehle; J Heinemeyer; P Franz; P F Behrens; R Jackisch; G B Landwehrmeyer; T J Feuerstein
Journal:  J Neurochem       Date:  2003-05       Impact factor: 5.372

9.  Remote changes in cortical excitability after stroke.

Authors:  Cathrin M Bütefisch; Johannes Netz; Marion Wessling; Rüdiger J Seitz; Volker Hömberg
Journal:  Brain       Date:  2003-02       Impact factor: 13.501

10.  Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis.

Authors:  H D Rosas; W J Koroshetz; Y I Chen; C Skeuse; M Vangel; M E Cudkowicz; K Caplan; K Marek; L J Seidman; N Makris; B G Jenkins; J M Goldstein
Journal:  Neurology       Date:  2003-05-27       Impact factor: 9.910

View more
  32 in total

Review 1.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 2.  Hyperkinetic disorders and loss of synaptic downscaling.

Authors:  Paolo Calabresi; Antonio Pisani; John Rothwell; Veronica Ghiglieri; Josè A Obeso; Barbara Picconi
Journal:  Nat Neurosci       Date:  2016-06-28       Impact factor: 24.884

Review 3.  Developmental origins of cortical hyperexcitability in Huntington's disease: Review and new observations.

Authors:  Carlos Cepeda; Katerina D Oikonomou; Damian Cummings; Joshua Barry; Vannah-Wila Yazon; Dickson T Chen; Janelle Asai; Christopher K Williams; Harry V Vinters
Journal:  J Neurosci Res       Date:  2019-07-28       Impact factor: 4.164

4.  The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.

Authors:  Daniel Ryskamp; Jun Wu; Michal Geva; Rebecca Kusko; Iris Grossman; Michael Hayden; Ilya Bezprozvanny
Journal:  Neurobiol Dis       Date:  2016-11-03       Impact factor: 5.996

Review 5.  Synaptic plasticity in neurodegenerative diseases evaluated and modulated by in vivo neurophysiological techniques.

Authors:  F Pilato; P Profice; F Ranieri; F Capone; R Di Iorio; L Florio; V Di Lazzaro
Journal:  Mol Neurobiol       Date:  2012-07-22       Impact factor: 5.590

Review 6.  Neurophysiological markers of network dysfunction in neurodegenerative diseases.

Authors:  Roisin McMackin; Peter Bede; Niall Pender; Orla Hardiman; Bahman Nasseroleslami
Journal:  Neuroimage Clin       Date:  2019-02-02       Impact factor: 4.881

Review 7.  Corticostriatal network dysfunction in Huntington's disease: Deficits in neural processing, glutamate transport, and ascorbate release.

Authors:  George V Rebec
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

Review 8.  Alteration of GABAergic neurotransmission in Huntington's disease.

Authors:  Maurice Garret; Zhuowei Du; Marine Chazalon; Yoon H Cho; Jérôme Baufreton
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

9.  Monitoring Huntington's disease progression through preclinical and early stages.

Authors:  Chris Tang; Andrew Feigin
Journal:  Neurodegener Dis Manag       Date:  2012-08-01

10.  Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness.

Authors:  Robert Christian Wolf; Georg Grön; Fabio Sambataro; Nenad Vasic; Nadine Donata Wolf; Philipp Arthur Thomann; Carsten Saft; G Bernhard Landwehrmeyer; Michael Orth
Journal:  Hum Brain Mapp       Date:  2011-08-25       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.